Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

Similar articles for PubMed (Select 21936567)

1.

Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.

Gyenis L, Duncan JS, Turowec JP, Bretner M, Litchfield DW.

J Proteome Res. 2011 Nov 4;10(11):4887-901. doi: 10.1021/pr2008994. Epub 2011 Oct 13.

2.

Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.

Gyenis L, Turowec JP, Bretner M, Litchfield DW.

Biochim Biophys Acta. 2013 Jul;1834(7):1352-8. doi: 10.1016/j.bbapap.2013.02.006. Epub 2013 Feb 14. Review.

PMID:
23416530
3.

An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.

Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA, Litchfield DW.

Mol Cell Proteomics. 2008 Jun;7(6):1077-88. doi: 10.1074/mcp.M700559-MCP200. Epub 2008 Feb 7.

4.

Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2.

Gyenis L, Kuś A, Bretner M, Litchfield DW.

J Proteomics. 2013 Apr 9;81:70-9. doi: 10.1016/j.jprot.2012.09.017. Epub 2012 Sep 25.

PMID:
23017496
5.

Protein kinase CK2 is a constitutively active enzyme that promotes cell survival: strategies to identify CK2 substrates and manipulate its activity in mammalian cells.

Turowec JP, Duncan JS, French AC, Gyenis L, St Denis NA, Vilk G, Litchfield DW.

Methods Enzymol. 2010;484:471-93. doi: 10.1016/B978-0-12-381298-8.00023-X.

PMID:
21036246
6.

Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation.

Venerando A, Franchin C, Cant N, Cozza G, Pagano MA, Tosoni K, Al-Zahrani A, Arrigoni G, Ford RC, Mehta A, Pinna LA.

PLoS One. 2013 Sep 18;8(9):e74232. doi: 10.1371/journal.pone.0074232. eCollection 2013.

7.
8.

Cell cycle regulatory protein p27KIP1 is a substrate and interacts with the protein kinase CK2.

Tapia JC, Bolanos-Garcia VM, Sayed M, Allende CC, Allende JE.

J Cell Biochem. 2004 Apr 1;91(5):865-79.

PMID:
15034923
9.

Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.

Laudet B, Barette C, Dulery V, Renaudet O, Dumy P, Metz A, Prudent R, Deshiere A, Dideberg O, Filhol O, Cochet C.

Biochem J. 2007 Dec 15;408(3):363-73.

10.

Casein kinase 2 binds and phosphorylates the nucleosome assembly protein-1 (NAP1) in Drosophila melanogaster.

Li M, Strand D, Krehan A, Pyerin W, Heid H, Neumann B, Mechler BM.

J Mol Biol. 1999 Nov 12;293(5):1067-84.

PMID:
10547286
11.

Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.

Li X, Rao V, Jin J, Guan B, Anderes KL, Bieberich CJ.

J Proteome Res. 2012 Jul 6;11(7):3637-49. doi: 10.1021/pr3000514. Epub 2012 Jun 18.

12.

Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.

Vilk G, Weber JE, Turowec JP, Duncan JS, Wu C, Derksen DR, Zien P, Sarno S, Donella-Deana A, Lajoie G, Pinna LA, Li SS, Litchfield DW.

Cell Signal. 2008 Nov;20(11):1942-51. doi: 10.1016/j.cellsig.2008.07.002. Epub 2008 Jul 6.

PMID:
18662771
13.

Protein kinase CK2 phosphorylates and upregulates Akt/PKB.

Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M.

Cell Death Differ. 2005 Jun;12(6):668-77.

14.

Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis.

Salvi M, Sarno S, Cesaro L, Nakamura H, Pinna LA.

Biochim Biophys Acta. 2009 May;1793(5):847-59. doi: 10.1016/j.bbamcr.2009.01.013. Epub 2009 Jan 31.

15.

Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells.

Sayed M, Pelech S, Wong C, Marotta A, Salh B.

Oncogene. 2001 Oct 25;20(48):6994-7005. Erratum in: Oncogene 2002 Apr;21(15):2446.

16.

Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.

Pagano MA, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Pinna LA.

J Med Chem. 2004 Dec 2;47(25):6239-47.

PMID:
15566294
17.

Mutation of recombinant catalytic subunit alpha of the protein kinase CK2 that affects catalytic efficiency and specificity.

Chaillot D, Declerck N, Niefind K, Schomburg D, Chardot T, Meunier JC.

Protein Eng. 2000 Apr;13(4):291-8.

19.

Enhanced binding of RNAP II CTD phosphatase FCP1 to RAP74 following CK2 phosphorylation.

Abbott KL, Renfrow MB, Chalmers MJ, Nguyen BD, Marshall AG, Legault P, Omichinski JG.

Biochemistry. 2005 Mar 1;44(8):2732-45.

PMID:
15723518
20.

Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

Gratz A, Kuckländer U, Bollig R, Götz C, Jose J.

Mol Cell Biochem. 2011 Oct;356(1-2):83-90. doi: 10.1007/s11010-011-0957-4. Epub 2011 Jul 13.

PMID:
21750981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk